We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly Prevails Against Teva’s Patent Case, Maintains Alimta Exclusivity Until 2022
Lilly Prevails Against Teva’s Patent Case, Maintains Alimta Exclusivity Until 2022
Eli Lilly & Co. had their patent sustained by a federal appeals court, barring generics manufacturer Teva Pharmaceuticals from marketing its own version of the billion-dollar cancer drug Alimta.